SCHEMBL48610

SCHEMBL48610

CC(=O)Nc1ccncc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.69
MDM2 Q00987 1/20 0.67
EPHX1 P07099 1/20 0.66
SMN1; SMN2 Q16637 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
HTT P42858 1/20 0.60
NAPRT Q6XQN6 1/20 0.60
HSD17B10 Q99714 1/20 0.60
KDM4E B2RXH2 3/20 0.59
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPT P10636 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
CA12 O43570 1/20 0.58
BRD4 O60885 1/20 0.58
NR1I2 O75469 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
MB P02144 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL11515613 0.98 TSHR (0.67) TSHRMDM2EPHX1SMN1; SMN2L3MBTL1
Hydrochloric Acid SCHEMBL11146958 0.98 TSHR (0.67) TSHRMDM2EPHX1SMN1; SMN2L3MBTL1
Acetic Acid SCHEMBL9762020 0.96 TSHR (0.65) TSHRMDM2EPHX1SMN1; SMN2L3MBTL1
SCHEMBL3728246 0.87 SMN1; SMN2 (0.76) TSHRMDM2EPHX1SMN1; SMN2L3MBTL1
SCHEMBL6331463 0.84 ALDH1A1 (0.68) TSHRSMN1; SMN2L3MBTL1HTTKDM4E
SCHEMBL9562395 0.82 TSHR (0.81) TSHRSMN1; SMN2L3MBTL1HTTKDM4E
SCHEMBL22009555 0.82 TSHR (0.60) TSHREPHX1SMN1; SMN2L3MBTL1HTT
SCHEMBL11230781 0.82 TSHR (1.00) TSHRSMN1; SMN2KMT2AMEN1ALDH1A1
Acetaminophen SCHEMBL2128715 0.82 MAPT (0.71) TSHREPHX1SMN1; SMN2L3MBTL1HTT
SCHEMBL13589544 0.82 MDM2 (0.61) TSHRMDM2EPHX1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO claimed
CN-115961374-A Thermotropic liquid crystal polymer fiber, non-woven fabric, and preparation method and application thereof 宁波聚嘉新材料科技有限公司 2023-04-14 CN claimed
CN-115210339-A Etching solution for titanium nitride and molybdenum conductive metal wires 弗萨姆材料美国有限责任公司 2022-10-18 CN claimed
CN-111186112-A Preparation method of novel thermotropic liquid crystal high-performance polyarylate film 宁波聚嘉新材料科技有限公司 2020-05-22 CN claimed
CN-107567445-A It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor 坎塞拉有限公司 2018-01-09 CN claimed
WO-2016124553-A1 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY KANCERA AB (SE) 2016-08-11 WO claimed
EP-2678342-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES Takeda Pharmaceutical Company Limited (JP) 2014-01-01 EP claimed
WO-2012148548-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-01 WO claimed
US-20080039490-A1 PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE PURDUE RESEARCH FOUNDATION (US) 2008-02-14 US claimed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US claimed
CN-1780821-A Heterocyclic kinase inhibitors. ABBOTT LAB (US) 2006-05-31 CN claimed
CN-1745064-A Pyridines for the treatment of damaged mammalian neural tissue PURDUE RESEARCH FOUNDATION (US) 2006-03-08 CN claimed
EP-1383748-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-01-28 EP claimed
WO-2002051983-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 US disclosed
US-4160830-A Cephalosporins TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-07-10 US disclosed
US-4135931-A PYRIDINIUM COMPOUND IN DEVELOPER FUJI PHOTO FILM CO., LTD. (JP) 1979-01-23 US disclosed
US-4065619-A ANTIBIOTIC TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE TSHR 4359/4885MDM2 1250/4885EPHX1 2078/4885
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, BRCA1 TSHR 2806/4885MDM2 4/4885EPHX1 4496/4885
US-12570645-B2 Uses of p53 x-ray co-crystal structures TP53, TP53BP1, ERCC2 TSHR 1092/4885MDM2 8/4885EPHX1 4549/4885
US-20080039490-A1 PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE P2RY4, INA, PMP22 TSHR 4400/4885MDM2 3943/4885EPHX1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.